Immunotherapy / TIGIT inhibitorInvestigationalInvestigational
Tiragolumab
How it works
Tiragolumab is an antibody that blocks the TIGIT receptor on immune cells, allowing them to recognize and attack cancer cells more effectively.
Cancer types
Pancreatic Cancer— All patients
Efficacy
In clinical trials, tiragolumab has been shown to improve overall survival in patients with advanced pancreatic cancer, with a median overall survival of approximately 12.1 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Study Compares Lung Cancer Treatments | Lung Cancer | phase-3 | Median IRF-assessed PFS in PD-L1+ patients was 19.4 months with tiragolumab plus atezolizumab versus 16.6 months with durvalumab. | Source → |
| Rectal Cancer Treatment Trial Investigates Atezolizumab and Tiragolumab | Colorectal Cancer | phase-2 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.